Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Block listing Interim Review

1 Oct 2018 14:57

RNS Number : 5737C
Vernalis PLC
01 October 2018
 

BLOCK LISTING SIX MONTHLY RETURN AND BLOCK LISTING APPLICATION

 

VERNALIS PLC (the "Company")

 

1 October 2018

 

Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 

Name of applicant:

Vernalis plc

Name of scheme(s):

2007 Long Term Incentive Scheme ("LTIP"); 2012 Value Builder Plan ("VBP"); and

2016 Executive Incentive Plan ("EIP")

Period of return (from / to):

From: 29/Mar/2018

To: 01/Oct/2018

Balance of unallotted securities under scheme(s) from previous return:

Total of 2,149,159 Ordinary 1p Shares, split:

· Under LTIP = 360,485 Ordinary 1p Shares

· Under VBP = 1,788,674 Ordinary 1p Shares

· Under EIP = nil Ordinary 1p Shares

Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period:

Total of 166,376 Ordinary 1p Shares, split:

· Under LTIP = 39,405 Ordinary 1p Shares

· Under VBP = 126,971 Ordinary 1p Shares

Less: Number of securities forfeited under scheme(s) during period:

Total of 30,526 Ordinary 1p Shares:

· Under LTIP = 30,526 Ordinary 1p Shares

· Under VBP = nil Ordinary 1p Shares

· Under EIP = nil Ordinary 1p Shares

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

Total of 1,952,257 Ordinary 1p Shares, split:

· Under LTIP = 290,554 Ordinary 1p Shares

· Under VBP = 1,661,703 Ordinary 1p Shares

· Under EIP = nil Ordinary 1p Shares

Number and class of securities originally admitted and the date of admission (including any additions):

No. of Ordinary 1p Shares

Date on which Shares were Admitted to Trading

350,000

6 November 2013, plus

1,049,317

12 May 2014, plus

1,058,184

12 May 2015, plus

1,638,364

30 September 2015, plus

1,189,296

1 April 2016, plus

499,612

31 March 2017, plus

1,788,674

2 October 2017, plus

95,654

5 April 2018

 

-- ends --

 

Enquiries:

 

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

David Mackney, Chief Financial Officer

 

Canaccord plc (Nominated Adviser and Broker):

+44 (0) 20 7523 8000

Henry Fitzgerald-O'Connor

Emma Gabriel

 

Evercore (Financial Adviser):

+44 (0) 20 7653 6000

Julian Oakley

Alan Beirne

 

 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, pharmaceutical company with significant expertise in drug development. The Group has two approved products: Moxatag®, a once-daily formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. Vernalis has also nine programmes in its NCE development pipeline in addition to significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Daiichi Sankyo, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis and Servier.

 

For further information about Vernalis, please visit www.vernalis.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRMBBJTMBAMBJP
Date   Source Headline
6th Mar 20125:29 pmRNSHolding(s) in Company
5th Mar 20125:39 pmRNSHolding(s) in Company
2nd Mar 20129:22 amRNSVoting Rights and Capital
28th Feb 201212:28 pmRNSResult of General Meeting
28th Feb 20127:00 amRNSResult of Open Offer
10th Feb 20124:53 pmRNSPublication of Combined Circular and Prospectus
10th Feb 20127:00 amRNSLicence Agreemt &Firm Placing &Placing &Open Offer
10th Feb 20127:00 amRNSVernalis and Tris Pharma Announce Collaboration
17th Jan 20127:00 amRNSVernalis & Servier Sign 3rd Oncology Collaboration
4th Jan 20127:00 amRNSVernalis enters collaboration with Genentech
19th Dec 20117:00 amRNSSecond Research Milestone Achieved
12th Dec 20117:00 amRNSVernalis Earns Final Milestone Payment from Ipsen
16th Nov 20117:00 amRNSInterim Management Statement
7th Nov 201111:43 amRNSHolding(s) in Company
3rd Oct 20117:00 amRNSMilestone Achieved and Collaboration Extended
28th Sep 20117:00 amRNSPositive Results for V158866 in Phase I Study
21st Sep 20117:00 amRNSResearch Milestone Achieved
8th Sep 20114:40 pmRNSSecond Price Monitoring Extn
8th Sep 20114:35 pmRNSPrice Monitoring Extension
24th Aug 20117:00 amRNSVernalis Initiates Phase I Trial of V81444
17th Aug 20115:16 pmRNSReplacement - Director/PDMR Shareholding
17th Aug 20114:35 pmRNSDirector/PDMR Shareholding
12th Aug 201110:00 amRNSDirector/PDMR Shareholding
5th Aug 201111:59 amRNSHolding(s) in Company
3rd Aug 20117:00 amRNSInterim results for six months ended 30 June 2011
3rd Aug 20117:00 amRNSAppointment of Non-Executive Director
2nd Aug 201111:30 amRNSVernalis Appoints Corporate Broker
22nd Jul 20117:00 amRNSNotice of Results for Six Months Ended 30 June '11
20th Jul 20117:00 amRNSAUY922 Update
5th Jul 20114:40 pmRNSSecond Price Monitoring Extn
5th Jul 20114:35 pmRNSPrice Monitoring Extension
15th Jun 201111:30 amRNSResult of AGM
8th Jun 20114:20 pmRNSHolding(s) in Company
26th May 20114:41 pmRNSSecond Price Monitoring Extn
26th May 20114:35 pmRNSPrice Monitoring Extension
26th May 20114:17 pmRNSListing Application, Voting Rights, Share Capital
23rd May 20114:58 pmRNSHolding(s) in Company
19th May 20114:40 pmRNSSecond Price Monitoring Extn
19th May 20114:35 pmRNSPrice Monitoring Extension
13th May 20117:00 amRNSTosedostat data to be presented at ASCO
11th May 20117:00 amRNSInterim Management Statement
6th May 20117:01 amRNSDirector/PDMR Shareholding
6th May 20117:00 amRNSDirector/PDMR Shareholding
4th May 20117:01 amRNSAnnual Information Update
4th May 20117:00 amRNSNotice of AGM
20th Apr 201111:57 amRNSHolding(s) in Company
12th Apr 20114:40 pmRNSSecond Price Monitoring Extn
12th Apr 20114:35 pmRNSPrice Monitoring Extension
12th Apr 20117:00 amRNSResults for the year ended 31 December 2010
12th Apr 20117:00 amRNSVernalis Regains A2A Receptor Antagonist Programme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.